Making and developing conformationally locked vaccine immunogens

Calder Biosciences, Inc. is a nano-scale molecular engineering company that is applying its platform technology to develop novel respiratory syncytial virus (RSV) and universal Influenza vaccines that both represent multi-billion dollar market opportunities with mitigated clinical risk.

Calder Biosciences Is Redefining Medicine

Novel RSV & Univeral Influenza Vaccines

Colored transmission electron micrograph of a human cell infected with influenza virus seen here budding from the cell surface (red). Magnification: x 8000 at 10cm

RSV Vaccine

Calder has applied its protein engineering technology to lock the most potent RSV vaccine immunogen in its most effective conformation, and we have demonstrated in preclinical animal models that our RSV immunogen has superior potency and stability over the best-in-breed comparator (GSK’s candidate).

Colored transmission electron micrograph of the respiratory syncytial virus (RSV) Respiratory syncytial virus. Colored transmission electron micrograph of the respiratory syncytial viruses (RSV), a member of the paramyxovirus group. Each virus (upper frame) consists of an RNA (ribonucleic acid) core enclosed in a protein coat within a phospholipid envelope. Magnification unknown.

Universal Flu Vaccine

Calder’s universal flu vaccine program focuses antibody responses on parts of the influenza surface protein (hemagglutinin) that are conserved across all strains. It will be broadly protective against all strains of influenza and will safeguard against this ever-present pandemic threat. Click the button below to learn more.